pc-spes
pc spes
Hormonal therapy and prostectomy
Brachytherapy , Radiation and Cryosurgery
Biopsy prostate and gleason score
Radiotherapy and chemo therapy
Alternative cancer treatment with spes
Prostate cancer treatment with pc spes


[About this website]
[What is prostate cancer]
[Pc spes - Prostate Cancer]
[Spes - other Cancers]
[Modified Citrus Pectin]
[PC SPES article 1]
[PC SPES article 2]
[PC SPES article 3]
[PC SPES article 4]
[PC SPES article 5]
[PC SPES article 6]
[PC SPES article 7]
[PC SPES article 8]
[PC SPES article 9]
[PC SPES article 10]
[ABC News movie 1]
[ABC News movie 2]
[SPES article 1]
[SPES article 2]
[Where to buy]
[Links to related sites]

Anti cancer properties and pain management of spes

ANTICANCER-PAIN POTENCY AND MECHANISM OF SPES

X. Wang, S. Chen, H. Huang
International Medical Research Clinical, Shangai, China

     Pain resulting from cancer is a major medical concern in the world.  Our research in this field has led to a natural novel product, SPES, for treating cancer pain and suppressing cancer metastasis.  Our studies included evaluation of analgesic tolerance, effects on peripheral pain-inducing substances, on pain sense electrophysiology and on anticancer potency at the genetic level.  Our results show no apparent differences in time and dose response of pain thresholds between SPES and morphine (p>0.05).  However, its analgesic effects are not inhibited by naloxone, suggesting a different mechanism.  SPES was also found to act through multiple sites.  So, SPES can significantly reduce cancer pain without having the adverse effects of opioids and improve the quality of life of terminally ill cancer patients, as well.
     Cancer pain resulting from malignant neoplasms is suffered by 3,500,000 patients all over the world every day.  Owing to this, the World Health Organization demands that most cancer pain should have been relieved by the year 2000.   Currently, the major method to treat cancer pain is to use drugs, which is not only inadequate but causes harmful effects.  Fortunately, SPES, made from natural herbs by using modern scientific microanalytic and biogenic pharmaceutical techniques, has been proved with traditional Chinese medicine to be a cancer killer, as well as an internal anticancer and analgesic modulator in the human body.  So, undoubtedly, it is SPES that is blazing a trail to treat cancer pain.

MATERIALS AND METHODS

     The clinical and experimental researches in this study concerned two aspects:  anticancer pain and anticancer.  By evaluating the anticancer potency of SPES (evaluations of clinical and experimental potency, analgesic tolerance and its relativity with opium receptors), explaining the effects of SPES on peripheral algogenic substance (PGF2a, PGE2, substance P contents in stomach cancer tissues, serum B-endorphin immunologically competent substance contents, intracerebral acetylcholine contents) and pain sense electrophysiology (pain-inducing potentials in spinal cord and cerebra and unit discharge in hypothalamic ARC regions), evaluating anticancer potency of SPES (experimental potency evaluation, dynamic researches into reproduction of hepatoma cells) and series of researches into effects of SPES on Cancer genetic expression (expression of gene phenotypes of hepatoma and genetic expressions of N-ras, IGF II of primary hepatoma), and tumor immunity

(natural killer cell activity and LPO content in peripheral blood), the potency and mechanism of the anticancer and analgesic effects of SPES come to light.
     By biogenic preparation techniques, SPES, a multiple compatible agent, composed of Agromania pilose ledeb, Corydalis bulbosa, Ganoderma gaponicum, Glycyrrhiza, Panax Ginseng, Rabdosia Tubescens, etc.  (United States patent pending), was made.  Considering 10 mg/kg (human dosage) as basis and using culturing models of neoplasms and carcinomas from patients in the terminal stage of cancer (hepatoma and stomach cancer patients) and experimental animals (mice, rats, nude mice, cats, etc.) and human cancer cell strains, radiation heat-causing tail-twitching test and radioimmunity detection, enzyme linking, biochemical antibodies, tissue ultrastructure observation, flowing cellular analysis, evoked potentials of nerve tissues and nit discharge of neuron detection and gene probes were adopted to attain satisfactory results.

RESULTS AND CONCLUSION

     In the clinical and experimental research, the following results of the analgesic effects of SPES were obtained:

1. SPES had the ability to eminently raise pain and pain tolerance thresholds (p<0.01), indicating the analgesic effects and duration of SPES > those of dihydroergotamine (Fig. 1), but SPES produced less side effects than dihydroergotamine (Table 1) and improved the quality of life (Fig 2).

2. No apparent differences in time-effect and dose-effect relationships of pain thresholds existed between the SPES and morphine groups (p>0.05)  (Fig. 3), but SPES suggested a stronger analgesic and tolerant ability, not to be antagonized by naloxone.

3. SPES obviously decreased PGF2a and PGE2 levels in sera (p<0.05), in addition, inhibited those in tissue (p<0.01).

4. In quiescent states, SPES was able to increase greatly after medication with SPES.

Figure 1 - Evaluation of average degree of anticancer-pain 24 h after effects of different drugs.

Table 1 - Comparison of clinical effects.
Legend - A: reaction; B: sleepiness; C: drowsiness; D: nausea; E: vomiting; F: anxiety; G: constipation; H: euphoria.

 


Figure 2 - Effects of cancer pain on relative norms of life quality after dosages of different drugs.
Legend - A: general activity; B: motion; C: ability to walk; D: appetite; E: sleep; F: delight of life; G: temperature.

5. Intracerebral Ach levels increased very markedly after using SPES (p<0.01).

6. SPES was able to effectively inhibit the wave amplitudes of P250-260 and prolong the latent periods.

7. SPES was observed to successfully suppress the increase in cellular discharge induced by somatic and visceral pain (p<0.01), reduce basically-discharged cells in number (p>0.05) and also inhibit evoked potentials of pain stimulation and the RGC frequency enhancement of the stimulation.

8. SPES, as well as morphine, markedly caused more ARC excitatory unit discharges (p<0.05) and greatly shortened the duration the damaging stimulation response required.

     Besides, in the aspect of anticancer, SPES, with granules that can enter the nuclear region, also demonstrates tumor growth- and cancer cell proliferation-inhibiting effects by decreasing the total unit area of survived hepatoma cells (Fig. 4), blocking duplication and division of DNA, appearance of heteroploids in hepatoma cells and overexpressions of N-ras genes and IGF II in human  primary hepatoma cells; and increasing RBC-SOD and serum SOD levels in cancer blood and natural killer cell activity.




Figure 3 - Time-effect relationships of pain thresholds affected by SPES and morphine.


Figure 4 - SPES is able to kill cancer cells.
1 - State of human hepatoma cells before medication of SPES.
2 - Human hepatoma cells denatured 12 h after effects of SPES.
3 - Human hepatomacells was damaged 24 h after effects of SPES.

     From these previous results the following conclusion can be made:
     Both animal model study and human clinical trials have demonstrated the high potency and low toxicity of SPES.  It is very effective in treating cancer and cancer pain.  While there is no apparent difference in time and dose response of pain thresholds between SPES and morphine, the analgesic effect of SPES is not inhibited by naloxone, suggesting a different mechanism.  At present, we are isolating and evaluating its novel active chemical compounds for potential anticancer and anticancer pain therapeutic agents.

REFERENCES

1. CHEN Q: Research Method in Chinese    Medical Pharmacology.  Beijing, People's Medicine Press, 1993.

2. Li GX: Toxicology and Clinical Practice of Chinese Medicine. Tianjing, Tianjing Scientific Translation Co., 1992.

3. JIANGSHU COLLEGE OF NEW CHINESE MEDICINE: Dictionary of Chinese Medicine., Shanghai, Shanghai People's Press, 1977.

4. HOLLAND JF: Cancer Medicine. Philadelphia, Lea & Febiger, 1982.

5. WEINDEG RA: A molecular basis of cancer. Scientific Amer 1983; 249(5):126.

1
Hosted by www.Geocities.ws